TY  - CONF
AU  - Gašić, Vladimir
AU  - Pravdić, Zlatko
AU  - Suvajdžić Vuković, Nada
AU  - Marjanović, Irena
AU  - Karan-Đurašević, Teodora
AU  - Pavlović, Sonja
AU  - Tošić, Nataša
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1899
AB  - Acute myeloid leukemia (AML) is a malignancy of hematopoetic tissue which occurs due to a halt in
differentiation, loss of proliferation control and dysregulated apoptosis of myeloid progenitor cells. In
many cancers, as well as AML, dysregulation of apoptosis constitutes the basis of pathogenesis and this
phenomenon is important for chemotherapy success. Pharmacotranscriptomic markers of AML
prognosis could be targets of specific therapy. The anti-apoptotic gene BCL2 (B-cell lymphoma protein
2), the pro-apoptotic BAX (BCL2-associated X) and genes involved in drug resistance, like MDR1
could have a significant impact on AML prognosis and therapy response. Bone-marrow samples at
diagnosis were collected from 51 adult patients with AML-NK. Expressions of BCL2, BAX and MDR1
were analysed using the real-time polymerase chain reaction method. Statistical evaluation was
performed. The presence of chemoresistance was found to be associated with overexpression of BCL2
(BCL2+) (p=0.018), while underexpression of BAX in patients has shown a greater affinity towards
relapse (p=0.034). Evaluating the expressions of BCL2 and BAX in a combined effect has shown that
87% of patients with BAX/BCL2low status were resistant to therapy (p=0.024). BCL2+ status was
associated with high expression of MDR1 (p<0.001). Likewise, high expression of MDR1 was
associated with the absence of NPM1 and FLT3-ITD mutations (p=0.048 and p=0.010, respectively).
This is the first study that focused only on AML-NK patients, when it comes to analysis of BCL2, BAX
and MDR1 gene expression profiles. The results of this preliminary study have shown that high BCL2
expression would likely lead to resistance from chemotherapy, making anti-BCL2 treatment a viable
option in patients with this expression profile. A study on a larger group of patients could clarify the
prognostic importance of the studied genes in adult AML-NK patients and improve the precision
medicine approach in the field of hematology.
PB  - Sarajevo : Institute for Genetic Engineering and Biotechnology, University of Sarajevo
C3  - Genetics & Applications
T1  - Expression levels of BCL2, BAX and MDR1 as pharmacotranscriptomic and prognostic markers of prognosis in acute myeloid leukemia
VL  - 7
VL  - 2 (Special edition)
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1899
ER  - 

@conference{
author = "Gašić, Vladimir and Pravdić, Zlatko and Suvajdžić Vuković, Nada and Marjanović, Irena and Karan-Đurašević, Teodora and Pavlović, Sonja and Tošić, Nataša",
year = "2023",
abstract = "Acute myeloid leukemia (AML) is a malignancy of hematopoetic tissue which occurs due to a halt in
differentiation, loss of proliferation control and dysregulated apoptosis of myeloid progenitor cells. In
many cancers, as well as AML, dysregulation of apoptosis constitutes the basis of pathogenesis and this
phenomenon is important for chemotherapy success. Pharmacotranscriptomic markers of AML
prognosis could be targets of specific therapy. The anti-apoptotic gene BCL2 (B-cell lymphoma protein
2), the pro-apoptotic BAX (BCL2-associated X) and genes involved in drug resistance, like MDR1
could have a significant impact on AML prognosis and therapy response. Bone-marrow samples at
diagnosis were collected from 51 adult patients with AML-NK. Expressions of BCL2, BAX and MDR1
were analysed using the real-time polymerase chain reaction method. Statistical evaluation was
performed. The presence of chemoresistance was found to be associated with overexpression of BCL2
(BCL2+) (p=0.018), while underexpression of BAX in patients has shown a greater affinity towards
relapse (p=0.034). Evaluating the expressions of BCL2 and BAX in a combined effect has shown that
87% of patients with BAX/BCL2low status were resistant to therapy (p=0.024). BCL2+ status was
associated with high expression of MDR1 (p<0.001). Likewise, high expression of MDR1 was
associated with the absence of NPM1 and FLT3-ITD mutations (p=0.048 and p=0.010, respectively).
This is the first study that focused only on AML-NK patients, when it comes to analysis of BCL2, BAX
and MDR1 gene expression profiles. The results of this preliminary study have shown that high BCL2
expression would likely lead to resistance from chemotherapy, making anti-BCL2 treatment a viable
option in patients with this expression profile. A study on a larger group of patients could clarify the
prognostic importance of the studied genes in adult AML-NK patients and improve the precision
medicine approach in the field of hematology.",
publisher = "Sarajevo : Institute for Genetic Engineering and Biotechnology, University of Sarajevo",
journal = "Genetics & Applications",
title = "Expression levels of BCL2, BAX and MDR1 as pharmacotranscriptomic and prognostic markers of prognosis in acute myeloid leukemia",
volume = "7, 2 (Special edition)",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1899"
}

Gašić, V., Pravdić, Z., Suvajdžić Vuković, N., Marjanović, I., Karan-Đurašević, T., Pavlović, S.,& Tošić, N.. (2023). Expression levels of BCL2, BAX and MDR1 as pharmacotranscriptomic and prognostic markers of prognosis in acute myeloid leukemia. in Genetics & Applications
Sarajevo : Institute for Genetic Engineering and Biotechnology, University of Sarajevo., 7.
https://hdl.handle.net/21.15107/rcub_imagine_1899

Gašić V, Pravdić Z, Suvajdžić Vuković N, Marjanović I, Karan-Đurašević T, Pavlović S, Tošić N. Expression levels of BCL2, BAX and MDR1 as pharmacotranscriptomic and prognostic markers of prognosis in acute myeloid leukemia. in Genetics & Applications. 2023;7.
https://hdl.handle.net/21.15107/rcub_imagine_1899 .

Gašić, Vladimir, Pravdić, Zlatko, Suvajdžić Vuković, Nada, Marjanović, Irena, Karan-Đurašević, Teodora, Pavlović, Sonja, Tošić, Nataša, "Expression levels of BCL2, BAX and MDR1 as pharmacotranscriptomic and prognostic markers of prognosis in acute myeloid leukemia" in Genetics & Applications, 7 (2023),
https://hdl.handle.net/21.15107/rcub_imagine_1899 .

TY  - JOUR
AU  - Pravdić, Zlatko
AU  - Vuković, Nada Suvajdžić
AU  - Gašić, Vladimir
AU  - Marjanović, Irena
AU  - Karan-Đurašević, Teodora
AU  - Pavlović, Sonja
AU  - Tošić, Nataša
PY  - 2023
UR  - https://sciendo.com/article/10.2478/raon-2023-0017
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2291
AB  - Background: Deregulation of the apoptotic process underlies the pathogenesis of many cancers, including leukemia, but is also very important for the success of chemotherapy treatment. Therefore, the gene expression profile of main apoptotic factors, such as anti-apoptotic BCL2 (B-cell lymphoma protein 2) and pro-apoptotic BAX (BCL2-associated X), as well as genes involved in the multi-drug resistance (ABCB1), could have significant impact on the prognosis and could be used as targets for specific therapy.Patients and methodsWe analyzed the expression of BCL2, BAX, and ABCB1 in bone-marrow samples collected at diagnosis from 51 adult patients with acute myeloid leukemia with normal karyotype (AML-NK) using real-time polymerase chain reaction method, and examined their prognostic potential.ResultsIncreased expression of BCL2 (BCL2+) was associated with the presence of chemoresistance (p = 0.024), while patients with low BAX expression were more prone to relapse (p = 0.047). Analysis of the combined effect of BCL2 and BAX expression showed that 87% of patients with BAX/BCL2low status were resistant to therapy (p = 0.044). High expression of ABCB1 was associated with BCL2+ status (p < 0.001), and with absence FLT3-ITD mutations (p = 0.019).ConclusionsThe present analysis of BCL2, BAX, and ABCB1 gene expression profiles is the first study focusing solely
PB  - Sciendo
T2  - Radiology and Oncology
T1  - The influence of BCL2, BAX, and ABCB1 gene expression on prognosis of adult de novo acute myeloid leukemia with normal karyotype patients
EP  - 248
IS  - 2
SP  - 239
VL  - 57
DO  - 10.2478/raon-2023-0017
ER  - 

@article{
author = "Pravdić, Zlatko and Vuković, Nada Suvajdžić and Gašić, Vladimir and Marjanović, Irena and Karan-Đurašević, Teodora and Pavlović, Sonja and Tošić, Nataša",
year = "2023",
abstract = "Background: Deregulation of the apoptotic process underlies the pathogenesis of many cancers, including leukemia, but is also very important for the success of chemotherapy treatment. Therefore, the gene expression profile of main apoptotic factors, such as anti-apoptotic BCL2 (B-cell lymphoma protein 2) and pro-apoptotic BAX (BCL2-associated X), as well as genes involved in the multi-drug resistance (ABCB1), could have significant impact on the prognosis and could be used as targets for specific therapy.Patients and methodsWe analyzed the expression of BCL2, BAX, and ABCB1 in bone-marrow samples collected at diagnosis from 51 adult patients with acute myeloid leukemia with normal karyotype (AML-NK) using real-time polymerase chain reaction method, and examined their prognostic potential.ResultsIncreased expression of BCL2 (BCL2+) was associated with the presence of chemoresistance (p = 0.024), while patients with low BAX expression were more prone to relapse (p = 0.047). Analysis of the combined effect of BCL2 and BAX expression showed that 87% of patients with BAX/BCL2low status were resistant to therapy (p = 0.044). High expression of ABCB1 was associated with BCL2+ status (p < 0.001), and with absence FLT3-ITD mutations (p = 0.019).ConclusionsThe present analysis of BCL2, BAX, and ABCB1 gene expression profiles is the first study focusing solely",
publisher = "Sciendo",
journal = "Radiology and Oncology",
title = "The influence of BCL2, BAX, and ABCB1 gene expression on prognosis of adult de novo acute myeloid leukemia with normal karyotype patients",
pages = "248-239",
number = "2",
volume = "57",
doi = "10.2478/raon-2023-0017"
}

Pravdić, Z., Vuković, N. S., Gašić, V., Marjanović, I., Karan-Đurašević, T., Pavlović, S.,& Tošić, N.. (2023). The influence of BCL2, BAX, and ABCB1 gene expression on prognosis of adult de novo acute myeloid leukemia with normal karyotype patients. in Radiology and Oncology
Sciendo., 57(2), 239-248.
https://doi.org/10.2478/raon-2023-0017

Pravdić Z, Vuković NS, Gašić V, Marjanović I, Karan-Đurašević T, Pavlović S, Tošić N. The influence of BCL2, BAX, and ABCB1 gene expression on prognosis of adult de novo acute myeloid leukemia with normal karyotype patients. in Radiology and Oncology. 2023;57(2):239-248.
doi:10.2478/raon-2023-0017 .

Pravdić, Zlatko, Vuković, Nada Suvajdžić, Gašić, Vladimir, Marjanović, Irena, Karan-Đurašević, Teodora, Pavlović, Sonja, Tošić, Nataša, "The influence of BCL2, BAX, and ABCB1 gene expression on prognosis of adult de novo acute myeloid leukemia with normal karyotype patients" in Radiology and Oncology, 57, no. 2 (2023):239-248,
https://doi.org/10.2478/raon-2023-0017 . .

TY  - CONF
AU  - Pavlović, Đorđe
AU  - Tošić, Nataša
AU  - Zukić, Branka
AU  - Pravdić, Zlatko
AU  - Suvajdžić Vuković, Nada
AU  - Pavlović, Sonja
AU  - Gašić, Vladimir
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1742
AB  - Akutna mijeloidna leukemija (AML) je heterogeno maligno oboljenje kako na
kliničkom tako i na genetičkom nivou. AML ima lošu prognozu, i zato postoji
konstantna potreba za novim prognostičkim markerima, kao i markerima koji
mogu biti mete za inovativne terapeutike. U skorije vreme potraga za novim
biomarkerima je naučnicima skrenula pažnju ka nekodirajućim RNK, naročito
dugim nekodirajućim RNK (dnkRNK) i mikroRNK (miRNK). U ovom radu ispitali
smo nivo ekspresije „growth arrest-specific transcript 5“ (GAS5) dnkRNK kod 94
mlađih osoba obolelih od AML, kao i nivo ekspresije miR-222 u grupi od 39
osoba obolelih od AML sa normalnim kariotipom (AML-NK), u cilju da
ispitamo njihov prognostički potencijal. Naši rezultati su pokazali da je nivo
ekspresije GAS5 kod obolelih od AML niži u poređenju sa zdravim kontrolama, i
češći je u grupi sa nepovoljnom prognozom. U AML-NK grupi pacijenti su imali
povišenu ekspresiju miR-222 u poređenju sa zdravim kontrolama. Sinergistički
efekat „GAS5low/miR-222 high“ nije utvrđen. Ovo je prva studija koja je ispitala
interakciju ekspresije GAS5 i miR-222 kod obolelih od AML. Naši rezultati
indikuju potrebu za daljim ispitivanjem ove dve nekodirajuće RNK i njihove
potencijalne uloge u leukemogenezi i prognostici AML pacijenata.
AB  - Акутна мијелоидна леукемија (АМЛ) је хетерогено малигно обољење како на
клиничком тако и на генетичком нивоу. АМЛ има лошу прогнозу, и зато постоји
константна потреба за новим прогностичким маркерима, као и маркерима који
могу бити мете за иновативне терапеутике. У скорије време потрага за новим
биомаркерима је научницима скренула пажњу ка некодирајућим РНК, нарочито
дугим некодирајућим РНК (днкРНК) и микроРНК (миРНК). У овом раду испитали
смо ниво експресије „growth arrest-specific transcript 5“ (GAS5) днкРНК код 94
млађих особа оболелих од АМЛ, као и ниво експресије miR-222 у групи од 39
особа оболелих од АМЛ са нормалним кариотипом (АМЛ-НК), у циљу да
испитамо њихов прогностички потенцијал. Наши резултати су показали да је ниво
експресије GAS5 код оболелих од АМЛ нижи у поређењу са здравим контролама, и
чешћи је у групи са неповољном прогнозом. У АМЛ-НК групи пацијенти су имали
повишену експресију miR-222 у поређењу са здравим контролама. Синергистички
ефекат „GAS5low/miR-222 high“ није утврђен. Ово је прва студија која је испитала
интеракцију експресије GAS5 и miR-222 код оболелих од АМЛ. Наши резултати
индикују потребу за даљим испитивањем ове две некодирајуће РНК и њихове
потенцијалне улоге у леукемогенези и прогностици АМЛ пацијената.
PB  - Beograd : Srpsko biološko društvo
C3  - Treći kongres biologa Srbije
T1  - Ekspresioni obrazac duge nekodirajuće RNK GAS5 i mikroRNK- 222 kod mlađih pacijenata obolelih od AML
T1  - Експресиони образац дуге некодирајуће РНК GAS5 и микроРНК- 222 код млађих пацијената оболелих од АМЛ
SP  - 302
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1742
ER  - 

@conference{
author = "Pavlović, Đorđe and Tošić, Nataša and Zukić, Branka and Pravdić, Zlatko and Suvajdžić Vuković, Nada and Pavlović, Sonja and Gašić, Vladimir",
year = "2022",
abstract = "Akutna mijeloidna leukemija (AML) je heterogeno maligno oboljenje kako na
kliničkom tako i na genetičkom nivou. AML ima lošu prognozu, i zato postoji
konstantna potreba za novim prognostičkim markerima, kao i markerima koji
mogu biti mete za inovativne terapeutike. U skorije vreme potraga za novim
biomarkerima je naučnicima skrenula pažnju ka nekodirajućim RNK, naročito
dugim nekodirajućim RNK (dnkRNK) i mikroRNK (miRNK). U ovom radu ispitali
smo nivo ekspresije „growth arrest-specific transcript 5“ (GAS5) dnkRNK kod 94
mlađih osoba obolelih od AML, kao i nivo ekspresije miR-222 u grupi od 39
osoba obolelih od AML sa normalnim kariotipom (AML-NK), u cilju da
ispitamo njihov prognostički potencijal. Naši rezultati su pokazali da je nivo
ekspresije GAS5 kod obolelih od AML niži u poređenju sa zdravim kontrolama, i
češći je u grupi sa nepovoljnom prognozom. U AML-NK grupi pacijenti su imali
povišenu ekspresiju miR-222 u poređenju sa zdravim kontrolama. Sinergistički
efekat „GAS5low/miR-222 high“ nije utvrđen. Ovo je prva studija koja je ispitala
interakciju ekspresije GAS5 i miR-222 kod obolelih od AML. Naši rezultati
indikuju potrebu za daljim ispitivanjem ove dve nekodirajuće RNK i njihove
potencijalne uloge u leukemogenezi i prognostici AML pacijenata., Акутна мијелоидна леукемија (АМЛ) је хетерогено малигно обољење како на
клиничком тако и на генетичком нивоу. АМЛ има лошу прогнозу, и зато постоји
константна потреба за новим прогностичким маркерима, као и маркерима који
могу бити мете за иновативне терапеутике. У скорије време потрага за новим
биомаркерима је научницима скренула пажњу ка некодирајућим РНК, нарочито
дугим некодирајућим РНК (днкРНК) и микроРНК (миРНК). У овом раду испитали
смо ниво експресије „growth arrest-specific transcript 5“ (GAS5) днкРНК код 94
млађих особа оболелих од АМЛ, као и ниво експресије miR-222 у групи од 39
особа оболелих од АМЛ са нормалним кариотипом (АМЛ-НК), у циљу да
испитамо њихов прогностички потенцијал. Наши резултати су показали да је ниво
експресије GAS5 код оболелих од АМЛ нижи у поређењу са здравим контролама, и
чешћи је у групи са неповољном прогнозом. У АМЛ-НК групи пацијенти су имали
повишену експресију miR-222 у поређењу са здравим контролама. Синергистички
ефекат „GAS5low/miR-222 high“ није утврђен. Ово је прва студија која је испитала
интеракцију експресије GAS5 и miR-222 код оболелих од АМЛ. Наши резултати
индикују потребу за даљим испитивањем ове две некодирајуће РНК и њихове
потенцијалне улоге у леукемогенези и прогностици АМЛ пацијената.",
publisher = "Beograd : Srpsko biološko društvo",
journal = "Treći kongres biologa Srbije",
title = "Ekspresioni obrazac duge nekodirajuće RNK GAS5 i mikroRNK- 222 kod mlađih pacijenata obolelih od AML, Експресиони образац дуге некодирајуће РНК GAS5 и микроРНК- 222 код млађих пацијената оболелих од АМЛ",
pages = "302",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1742"
}

Pavlović, Đ., Tošić, N., Zukić, B., Pravdić, Z., Suvajdžić Vuković, N., Pavlović, S.,& Gašić, V.. (2022). Ekspresioni obrazac duge nekodirajuće RNK GAS5 i mikroRNK- 222 kod mlađih pacijenata obolelih od AML. in Treći kongres biologa Srbije
Beograd : Srpsko biološko društvo., 302.
https://hdl.handle.net/21.15107/rcub_imagine_1742

Pavlović Đ, Tošić N, Zukić B, Pravdić Z, Suvajdžić Vuković N, Pavlović S, Gašić V. Ekspresioni obrazac duge nekodirajuće RNK GAS5 i mikroRNK- 222 kod mlađih pacijenata obolelih od AML. in Treći kongres biologa Srbije. 2022;:302.
https://hdl.handle.net/21.15107/rcub_imagine_1742 .

Pavlović, Đorđe, Tošić, Nataša, Zukić, Branka, Pravdić, Zlatko, Suvajdžić Vuković, Nada, Pavlović, Sonja, Gašić, Vladimir, "Ekspresioni obrazac duge nekodirajuće RNK GAS5 i mikroRNK- 222 kod mlađih pacijenata obolelih od AML" in Treći kongres biologa Srbije (2022):302,
https://hdl.handle.net/21.15107/rcub_imagine_1742 .

TY  - JOUR
AU  - Pavlović, Đorđe
AU  - Tošić, Nataša
AU  - Zukić, Branka
AU  - Pravdić, Zlatko
AU  - Suvajdžić-Vuković, Nada
AU  - Pavlović, Sonja
AU  - Gašić, Vladimir
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1573
AB  - Acute myeloid leukemia (AML) is a heterogeneous malignant disease both on clinical and genetic levels. AML has poor prognosis and, therefore, there is a constant need to find new prognostic markers, as well as markers that can be used as targets for innovative therapeutics. Recently, the search for new biomarkers has turned researchers' attention towards non-coding RNAs, especially long non-coding RNAs (lncRNAs) and micro RNAs (miRNAs). We investigated the expression level of growth arrest-specific transcript 5 (GAS5) lncRNA in 94 younger AML patients, and also the expression level of miR-222 in a cohort of 39 AML patients with normal karyotype (AML-NK), in order to examine their prognostic potential. Our results showed that GAS5 expression level in AML patients was lower compared to healthy controls. Lower GAS5 expression on diagnosis was related to an adverse prognosis. In the AML-NK group patients had higher expression of miR-222 compared to healthy controls. A synergistic effect of GAS5(low)/miR-222(high) status on disease prognosis was not established. This is the first study focused on examining the GAS5 and miR-222 expression pattern in AML patients. Its initial findings indicate the need for further investigation of these two non-coding RNAs, their potential roles in leukemogenesis, and the prognosis of AML patients.
PB  - MDPI, Basel
T2  - Diagnostics
T1  - Expression Profiles of Long Non-Coding RNA GAS5 and MicroRNA-222 in Younger AML Patients
IS  - 1
VL  - 12
DO  - 10.3390/diagnostics12010086
ER  - 

@article{
author = "Pavlović, Đorđe and Tošić, Nataša and Zukić, Branka and Pravdić, Zlatko and Suvajdžić-Vuković, Nada and Pavlović, Sonja and Gašić, Vladimir",
year = "2022",
abstract = "Acute myeloid leukemia (AML) is a heterogeneous malignant disease both on clinical and genetic levels. AML has poor prognosis and, therefore, there is a constant need to find new prognostic markers, as well as markers that can be used as targets for innovative therapeutics. Recently, the search for new biomarkers has turned researchers' attention towards non-coding RNAs, especially long non-coding RNAs (lncRNAs) and micro RNAs (miRNAs). We investigated the expression level of growth arrest-specific transcript 5 (GAS5) lncRNA in 94 younger AML patients, and also the expression level of miR-222 in a cohort of 39 AML patients with normal karyotype (AML-NK), in order to examine their prognostic potential. Our results showed that GAS5 expression level in AML patients was lower compared to healthy controls. Lower GAS5 expression on diagnosis was related to an adverse prognosis. In the AML-NK group patients had higher expression of miR-222 compared to healthy controls. A synergistic effect of GAS5(low)/miR-222(high) status on disease prognosis was not established. This is the first study focused on examining the GAS5 and miR-222 expression pattern in AML patients. Its initial findings indicate the need for further investigation of these two non-coding RNAs, their potential roles in leukemogenesis, and the prognosis of AML patients.",
publisher = "MDPI, Basel",
journal = "Diagnostics",
title = "Expression Profiles of Long Non-Coding RNA GAS5 and MicroRNA-222 in Younger AML Patients",
number = "1",
volume = "12",
doi = "10.3390/diagnostics12010086"
}

Pavlović, Đ., Tošić, N., Zukić, B., Pravdić, Z., Suvajdžić-Vuković, N., Pavlović, S.,& Gašić, V.. (2022). Expression Profiles of Long Non-Coding RNA GAS5 and MicroRNA-222 in Younger AML Patients. in Diagnostics
MDPI, Basel., 12(1).
https://doi.org/10.3390/diagnostics12010086

Pavlović Đ, Tošić N, Zukić B, Pravdić Z, Suvajdžić-Vuković N, Pavlović S, Gašić V. Expression Profiles of Long Non-Coding RNA GAS5 and MicroRNA-222 in Younger AML Patients. in Diagnostics. 2022;12(1).
doi:10.3390/diagnostics12010086 .

Pavlović, Đorđe, Tošić, Nataša, Zukić, Branka, Pravdić, Zlatko, Suvajdžić-Vuković, Nada, Pavlović, Sonja, Gašić, Vladimir, "Expression Profiles of Long Non-Coding RNA GAS5 and MicroRNA-222 in Younger AML Patients" in Diagnostics, 12, no. 1 (2022),
https://doi.org/10.3390/diagnostics12010086 . .